The value of sequential, alternating and consolidation chemotherapy in advanced non-small-cell lung cancer
- VernacularTitle:序贯、交替、巩固化疗对晚期非小细胞肺癌的价值
- Author:
Lanmei ZHANG
;
Ziming LI
;
Shun LU
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung;
Antineoplastic combined chemotherapy protocols
- From:
Cancer Research and Clinic
2008;20(5):357-360
- CountryChina
- Language:Chinese
-
Abstract:
A platinum-based doublet with a third-generation agent represents the standard first-line treatment for advanced non-small cell lung cancer patients with good performance status (PS). Traditional chemotherapy provides response rates of 20 %-40 % and a median survival of 8-10 months. In an attempt to improve its outcome, alternative schedules have been proposed, namely sequential, alternating, and maintenance therapy. Sequential chemotherapy with a platinum-based doublet followed by a single agent is feasible in patients with good PS; The use of sequential single agents is an option for elderly and frail patients unsuitable for a platinum-based combination. Based on trials published so far, it is unlikely that an alternating chemotherapy strategy will be proved superior to standard chemotherapy in patients with good PS.Consolidation chemotherapy may provide additional benefit for patients achieving disease control after standard first-line chemotherapy.
